|
IPM reports 9% growth in second quarter ended June, 2023: IQVIA
|
|
Gireesh Babu, New Delhi
September 16 , 2023
|
|
|
The Indian Pharmaceutical Market (IPM) has reported a growth of nine per cent in the second quarter of the current fiscal year, at around Rs. 51,400 crore as compared to around Rs. 47,000 crore registered during the same period of previous fiscal year, according to the quarterly analysis report from analytics major IQVIA.
The overall IPM market size has reported a growth of 11 per cent monthly average total (MAT) to Rs. 20,5000 crore as against Rs. 185,000 crore in 2022. However, the sales value growth in the second quarter ended June, 2023 was a meagre two per cent compared to the Rs. 50,000 crore MAT reported in the sequential quarter ended March, 2023.
Out of the total MAT of Rs. 51,400 crore, almost 39 per cent is chronic therapeutic areas (TAs) such as cardiac, chronic respiratory, anti-diabetes and neuro/central nervous system (CNS), while the rest of 61 percent comprises acute TAs including anti-infectives, acute respiratory, pain and gastro-intestinal therapies.
The chronic therapeutic areas (TAs) growth was at 10 per cent on previous period growth (PPG) matrics during the second quarter, outperforming the eight per cent growth of acute TAs.
Amongst the chronic TAs, cardiac segment registered growth of 10 per cent (PPG) and led in terms of absolute incremental value, followed by chronic respiratory at 14 per cent and neuro/CNS at nine per cent (both PPG). The antineoplastic, pain, uro and hormones also registered double digit growth during the quarter, it added.
Statins and hypotensive, which together contribute 39 per cent of the cardiac TA sales, grew at 11 per cent and 12 per cent (PPG), respectively. Anticoagulants grew by 13 per cent (PPG) majorly due to Ticagrelor and Apixaban both growing at 27 per cent and 31 per cent, respectively, said the quarterly report.
In respiratory TA, while the montelukast and combination market grew at 12 per cent, the bilastine+montelukast combination showed an exceptional growth of 34 per cent (PPG), it added.
In anti-diabetes TA, glimepiride metformin oral dose and glimipiride+metformin+voglibose reported seven and eight per cent growth respectively, and both vildagliptin and vildagliptin combination degrew at 20 percent and five per cent (PPG) respectively. Insulin market showed single digit growth of four per cent (PPG), it added.
In neuro/CNS category, antidepressant and anti-epileptics segments, which together constitutes 51 per cent of the TA, grew at nine and eight per cent (PPG) respectively. Gabapentin+nortriptylin within antiepileptics has shown high growth of 16 per cent (PPG) and brivaracetam showed fastest rate of growth at 50 per cent (PPG).
In the acute TAs market, cephalosporins, which contributes around 44 per cent of total anti-infectives market, grew by 11 per cent (PPG, while macrolides and carbapenems grew at 20 per cent and 16 per cent (PPG) respectively. Azithromycin contributing to around 61 per cent of macrolides grew at 15 percent, it added.
In respiratory segment, cough preparations, which contributes to around 50 per cent of the total therapy sales, has shown growth of 14 per cent PPG. However, cold preparations degrew at around three per cent majorly due to cold preparation liquid market which degrew by around nine per cent.
In the pain therapy area, the antirheumatic, nonsteroidal market, which contributes to 44 per cent of the pain market, reported a growth of eight per cent, while anti-pyretics grew at 13 per cent, during the period. Paracetamol oral solids have shown a double digit growth of 34 per cent whereas the liquid formulations have shown degrowth of around three per cent, it added.
In gastro-intestinal TA, antipeptic ulcerants and laxatives market grew at seven per cent, while pantoprazole+domperidone and rabeprazole+domperidone continued to grow at six per cent each, it added.
The report said that the Indian companies reported a faster growth at nine per cent (PPG) compared to multinational companies, which grew at six per cent (PPG) for the second quarter. Intas Pharmaceuticals, Mankind Pharma, Cipla and Macleods reflected good growths among top Indian pharma companies, while Abbott, GSK and AstraZeneca reflected good growths among top MNC pharma companies. The number of new launches in 2023 has increased by 32 per cent as compared to 2022, it said.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|